Statement of Principles concerning hepatitis B infection (Reasonable Hypothesis) (No. 9 of 2026)

The central concept is the reasonable hypothesis standard. Under section 120A of the VEA, a claim for operational service cannot succeed unless the material raises a reasonable hypothesis connecting the injury or disease to service, and that hypothesis must be consistent with a relevant SoP. This instrument supplies the template: if at least one of the listed factors exists and is related to service, a reasonable hypothesis is raised. If no factor exists, the hypothesis is not reasonable for the purposes of the Act. The factors themselves are of two types. Factors 9(1) to 9(5) address clinical onset of hepatitis B infection: percutaneous or permucosal exposure to infected body substances at least 30 days before onset; living or working for 90 continuous days in an area with at least 2% chronic prevalence; being a prisoner of war of Japan; serving in South-East Asia, the Mediterranean or the Pacific during World War 2; or inability to access appropriate vaccination or post-exposure prophylaxis before exposure. Factors 9(6) to 9(18) address clinical worsening of chronic hepatitis B: immunosuppressive medication in the preceding 5 years; HIV infection; solid organ, stem cell or bone marrow transplant; radiotherapy to the liver; alcohol consumption thresholds (55 kg for females, 110 kg for males over 10 years); diabetes mellitus for at least 5 years; surgical resection of hepatocellular carcinoma within 2 years; pregnancy or postpartum within 6 months; severe hepatic iron overload; chronic schistosomiasis involving the liver; hepatitis A, C, D or E infection; and inability to obtain appropriate clinical management. A key distinction is that the worsening factors apply only where the infection was suffered or contracted before or during, but did not arise out of, the person's relevant service (section 10(2)). This prevents double-counting where the original infection was already service-related. Clinical onset is defined as the point backwards in time from the first date of laboratory confirmation to the date when symptoms were persistently present as assessed by a registered medical practitioner. This definition is new and more precise than in previous versions; it anchors onset to symptoms rather than to the first positive test, which can be important for establishing temporal relationships with factors. Hepatitis B infection is defined as infection with the hepatitis B virus resulting in an illness characterised by inflammation of the liver, confirmed by serological or nucleic acid markers, and includes both acute and chronic infection. The instrument also notes that the ICD-10-AM codes B16, B18.0 and B18.1 apply but the definition controls. Relevant service is defined exhaustively as operational service, peacekeeping service, hazardous service or British nuclear test defence service under the VEA, and warlike or non-warlike service under the MRCA. The instrument does not cover peacetime service under the VEA that is not classified as one of these categories.

The instrument directly affects any person who has rendered relevant service as defined and who claims that hepatitis B infection or death from hepatitis B infection is connected to that service. This includes veterans of the Australian Defence Force who served in operational, peacekeeping, hazardous or British nuclear test defence capacities under the VEA, and members who rendered warlike or non-warlike service under the MRCA. It also affects dependants who claim for death from hepatitis B infection. The instrument is binding on the Repatriation Commission and the Military Rehabilitation and Compensation Commission when making primary decisions, and on the Veterans' Review Board and the Administrative Appeals Tribunal when reviewing those decisions. Medical practitioners who assess veterans for the purposes of compensation claims are affected because the definition of clinical onset requires their assessment of when symptoms were persistently present. The instrument indirectly affects the legal profession, especially veterans' advocates and lawyers who must map a client's factual circumstances to the listed factors. The Repatriation Medical Authority itself is the rule-maker, but its discretion is constrained by the requirement that factors be based on sound medical-scientific evidence. The instrument also affects the broader veteran community because it sets a precedent for how the Authority handles similar infections and diseases. Taxpayers bear the cost of claims that succeed under the SoP, and also bear the administrative cost of processing claims. The instrument does not affect civilians who have never rendered relevant service. From a free market perspective, the SoP system reduces the autonomy of courts and tribunals to determine causation on the merits of individual cases; it replaces that discretion with a centralised list developed by a statutory authority. This reduces uncertainty for government (a concentrated benefit) but imposes a uniform standard that may not accommodate atypical presentations or emerging medical evidence not yet considered by the Authority. The instrument makes no provision for cost recovery or market pricing of the risks it addresses; it is a pure transfer mechanism funded by compulsory taxation.

The instrument does not create rights directly; it operates as a condition precedent for the right to compensation under the VEA and MRCA. The key right it confers is the right of a claimant to have a reasonable hypothesis assessed by reference to the enumerated factors. If a claimant can establish at least one factor that is related to their service, they have satisfied the SoP component of the reasonable hypothesis test. Conversely, the instrument imposes no duties on the claimant beyond the evidentiary burden of proving the factor exists and is service-related. It imposes a duty on decision-makers to apply the SoP as a binding legislative instrument: where a factor exists and is related to service, the decision-maker must accept that a reasonable hypothesis has been raised (subject to other provisions of the VEA). Where no factor exists, the decision-maker must find that no reasonable hypothesis has been raised (again, subject to the possibility of other pathways under the Act). The instrument also creates an implicit duty on the Repatriation Medical Authority to base its factors on sound medical-scientific evidence, but that duty is owed to the Minister and Parliament, not directly to claimants. The instrument does not confer any private right of action or contractual right. It does not alter the standard of proof for the ultimate decision on entitlement; that remains governed by section 120 of the VEA (reasonable satisfaction for operational service, balance of probabilities for other service). The instrument also does not affect the right of internal review or merits review, nor the right to seek judicial review of a decision. For worsening factors, section 10(2) imposes a limitation: factors in 9(6) to 9(18) apply only where the infection was contracted before or during service but did not arise out of service. That means a claimant whose infection was already accepted as service-related cannot use those worsening factors to argue that a subsequent worsening is also service-related (though the original infection already covers the condition). This is a subtle but important constraint that prevents double recovery or multiplication of claims for the same condition.

The instrument itself contains no penal provisions. However, it operates within a broader statutory framework that does include penalties. Making a false or misleading statement in support of a claim for veterans' benefits is an offence under sections 137.1 and 137.2 of the Criminal Code, carrying maximum penalties of 12 months imprisonment (for reckless false statements) to 10 years (for intentional false statements). The SoP can indirectly trigger enforcement action because it defines the criteria that a claimant must meet; if a claimant fabricates exposure, vaccination history, or alcohol consumption to meet a factor, that could constitute a false statement. The instrument also sets a benchmark for medical certification: signed statements from medical practitioners regarding clinical onset or the existence of conditions like iron overload must be accurate. Enforcement of the SoP itself is through the claims and review process: if a decision-maker incorrectly applies the SoP, the remedy is internal review, merits review in the Veterans' Review Board or Administrative Appeals Tribunal, or judicial review in the Federal Court or High Court. There is no penalty against the decision-maker for misapplying the SoP, though systemic errors may lead to administrative sanctions. The instrument does not create any private enforcement mechanism. For the Repatriation Medical Authority, there is no penalty for making a SoP that is later found to be flawed, though its instrument can be set aside on judicial review if it is ultra vires or fails to take into account relevant considerations. The absence of penalties within the SoP itself is consistent with its character as a legislative instrument that sets criteria rather than imposing obligations. However, the practical penalty for a claimant who fails to meet any factor is denial of a potentially life changing disability pension. That is a severe de facto penalty, and the instrument's rigid factor list can operate harshly on claimants whose circumstances fall outside the Authority's pre-determined pathways. The instrument also creates incentives for rent-seeking: once a factor is listed, lawyers and advocates will invest in gathering evidence for that factor even if the underlying medical plausibility is weak, and the Authority may respond by making factors more restrictive in future revisions.

The instrument is made under subsection 196B(2) of the VEA and must be read together with the VEA and MRCA. Its primary interaction is with section 120A of the VEA (standard of proof for operational service) and section 338 of the MRCA (equivalent provision for warlike and non-warlike service). Under section 120A, a hypothesis is not reasonable unless it is consistent with the relevant SoP. This means the SoP overrides general principles of causation in tort or workers' compensation. It also interacts with other SoPs: section 11 of this instrument provides that if a factor refers to an injury or disease for which another SoP exists, the factors in that other SoP apply as in force from time to time. For example, factor 9(7) refers to HIV infection; if there is a SoP for HIV, the definition and factors of that SoP are incorporated by reference. This creates a cascading set of requirements that a practitioner must check. The instrument also interacts with the Health Insurance Act 1973 because the definition of hepatitis B infection requires laboratory testing, which is generally covered by Medicare. It interacts with the Therapeutic Goods Act 1989 because factor 9(5) refers to hepatitis B vaccination and post-exposure prophylaxis, which are therapeutic goods regulated by the TGA. The instrument does not interact with state or territory workers' compensation laws because it is exclusively a Commonwealth veterans' measure. It does not interact with the Criminal Code except as noted under penalties. The definition of ICD-10-AM codes references the Tenth Edition published by the Independent Hospital Pricing Authority, which is a Commonwealth authority under the National Health Reform Act 2011. The instrument does not confer jurisdiction on any court; jurisdiction arises under the VEA and the Administrative Appeals Tribunal Act 1975. The instrument also must be read consistently with the Human Rights (Parliamentary Scrutiny) Act 2011, though no statement of compatibility is attached. From a free market perspective, the interaction with other SoPs creates a web of regulatory requirements that increase the complexity of making a claim, thereby raising the cost of compliance. The incorporation by reference mechanism saves the Authority from redefining diseases in every SoP but imposes a burden on claimants to track multiple instruments. The instrument overrides common law causation principles, displacing the adversarial testing of expert evidence with a centralised regulatory determination.

The instrument repeals the Statement of Principles concerning hepatitis B (Reasonable Hypothesis) (No. 13 of 2017) (F2017L00001). That previous instrument was also made under subsection 196B(2) of the VEA. The new instrument was made on 19 December 2025 and commences on 19 January 2026. The number "No. 9 of 2026" indicates it is the ninth SoP made in the 2026 calendar year (though made in 2025, it takes effect in 2026). The period between 2017 and 2026 represents approximately nine years of medical evidence evolution. The text does not disclose what specific medical evidence led to the changes, but the differences are apparent: the 2017 version (not provided) can be compared to this one to see which factors were added, removed or revised. The new instrument includes explicit factors for being a prisoner of war of Japan (factor 9(3)) and service in South-East Asia, Mediterranean or Pacific during World War 2 (factor 9(4)), which were likely present in the 2017 version given they appeared in many older SoPs. The instrument also includes a new definition of clinical onset that is more detailed than the previous version, which may have caused litigation. The addition of the note about clinical onset in section 7(2) notes that the date of laboratory evidence usually follows clinical onset, which may be an attempt to clarify a point of contention. The instrument also changes the definition of hepatitis B infection to include explicit reference to nucleic acid markers (not just serological markers), reflecting advances in diagnostic testing. The alcohol consumption thresholds (55 kg for females, 110 kg for males) are retained from previous versions. The instrument does not include a sunset clause or a review date; SoPs are required to be reviewed when new medical evidence emerges but there is no fixed period. The Repatriation Medical Authority has the discretion to amend or replace SoPs at any time. The amendment history shows a pattern of incremental change rather than radical overhaul, suggesting the Authority is cautious about adding new factors without strong evidence. The repeal of the 2017 SoP means that any claim pending at commencement that has not been finally determined must be assessed against the new instrument, unless a transitional provision in the VEA preserves the old instrument (the VEA generally applies the SoP in force at the time of decision, but specific rules apply). Practitioners must check the date of decision.

The instrument itself does not name any cases, and the user has provided no litigation history. However, Statements of Principles under the VEA are among the most litigated Commonwealth legislative instruments. The Federal Court and the High Court have considered the validity of SoPs, the meaning of "reasonable hypothesis", and the interpretation of specific factors. The instrument's definition of clinical onset, for example, has been the subject of dispute: whether it refers to the first symptom or the first medical diagnosis. The current instrument attempts to resolve that by defining clinical onset as the point backwards from laboratory confirmation to the date when symptoms were persistently present. This is likely a response to judicial decisions that found ambiguity. The instrument's list of factors is not exhaustive of all possible causal pathways; the VEA still allows a claim to succeed if there is a reasonable hypothesis that is not covered by a SoP, though the Authority has argued that the SoP system is intended to be comprehensive. The case law on that point remains in tension. The instrument's distinction between onset factors and worsening factors may also generate litigation, particularly where a claimant had chronic hepatitis B before service and argues that service caused a worsening. Section 10(2) limits worsening factors to situations where the infection did not arise out of service. That provision may be challenged as inconsistent with the VEA's coverage of aggravation. The instrument also incorporates by reference other SoPs; litigation over the meaning of a factor in a referred SoP can affect this instrument. The instrument provides no guidance on the meaning of "appropriate clinical management" in factor 9(18), which is likely to be contested: what is appropriate? Whose standards? What if the veteran refused treatment? The instrument does not define "contemporary medical standards" in factor 9(5). These gaps are inevitable in a regulatory instrument that tries to capture complex medical realities in brief text. The litigation history under the previous 2017 SoP would have influenced the wording of this instrument, but the source document does not disclose that. Practitioners should be alert to the fact that Federal Court decisions interpreting the 2017 SoP may be relevant to the new instrument if the wording is identical or substantially similar.

Several features of this instrument can trap the unwary practitioner or claimant. First, the definition of clinical onset is counterintuitive: it works backwards from the first positive laboratory test to the date when symptoms were persistently present. This means that if a person had symptoms for years but only sought testing recently, the clinical onset date may be years before the test. Conversely, if a person had no symptoms but was tested incidentally and found positive, the clinical onset date is the same as the test date (because there are no earlier symptoms). This can be difficult to prove without contemporaneous medical records. Second, factor 9(1) requires exposure to a body substance derived from a person infected with the hepatitis B virus. It is not enough to show exposure to blood or bodily fluids in an environment with a high prevalence of hepatitis B; the actual source person must be proven infected. This is a high evidentiary burden for many veterans, especially those who served in conflict zones where medical records of the source are unavailable. Third, factor 9(2) requires a continuous period of at least 90 days in an area with a population prevalence of at least 2% chronic hepatitis B. The instrument does not define what counts as an "area" (country, region, town, military base) nor does it specify which source of prevalence data is authoritative. This factor may be practically impossible to prove without expert epidemiological evidence. Fourth, factor 9(5) requires inability to access appropriate hepatitis B vaccination before exposure to hepatitis B virus, or appropriate hepatitis B post-exposure prophylaxis, in accordance with contemporary medical standards. This raises several questions: what were the contemporary medical standards at the time of the veteran's service? Was the vaccine available? Was the veteran in a location where it could have been administered? Does "inability" include failure of the military medical system to offer it? The factor does not specify whether the veteran must have sought vaccination or whether it was the military's duty to provide it. Fifth, the alcohol consumption thresholds (55 kg for females, 110 kg for males) apply only to clinical worsening of chronic hepatitis B, not to clinical onset. A claimant who drinks heavily and develops acute hepatitis B cannot use this factor; they would need one of the onset factors. Sixth, factor 9(18) "inability to obtain appropriate clinical management for hepatitis B infection before clinical worsening" is a catch-all that might be invoked in many cases, but the instrument does not define "appropriate clinical management" or "inability". If a veteran was not offered antiviral therapy for financial reasons or because of remote location, it is unclear whether that qualifies. Seventh, the instrument only applies to relevant service as defined; peacetime service that is not operational, hazardous, peacekeeping, British nuclear test defence, warlike or non-warlike is excluded. A veteran who served only in Australia in a non-deployed role may not be covered. Eighth, the instrument does not address hepatitis B reactivation explicitly, though Note 2 mentions it as possible clinical worsening. The factors for worsening may not capture all reactivation scenarios. Ninth, the instrument defines iron overload as confirmed by elevated ferritin or transferrin saturation levels but does not specify the threshold for "elevated". That invites subjective interpretation. Tenth, the instrument's interaction with other SoPs via section 11 means that if a factor references another disease, the claimant must also satisfy that disease's SoP factors. This can create a cascade of evidentiary requirements.

For a claimant or their representative, compliance with the SoP involves a structured process of evidence gathering and analysis. Step one: confirm that the person rendered relevant service as defined (operational, peacekeeping, hazardous, British nuclear test defence under VEA, or warlike or non-warlike under MRCA). Step two: confirm the diagnosis of hepatitis B infection using the instrument's definition: infection confirmed by laboratory testing for serological or nucleic acid markers, with symptoms of liver inflammation. Obtain medical reports that document both the laboratory evidence and the clinical picture (fever, tiredness, jaundice, etc.). Step three: determine whether the claim concerns clinical onset of acute or chronic hepatitis B, or clinical worsening of chronic hepatitis B. This distinction dictates which factors apply. If the claim is for clinical onset, only factors 9(1) to 9(5) are relevant. If the claim is for clinical worsening, factors 9(6) to 9(18) are relevant, but only if the infection was contracted before or during service and did not arise out of service (section 10(2)). Step four: for each potentially relevant factor, gather evidence that supports the existence of the factor and a temporal relationship to service. For factor 9(1): document any percutaneous or permucosal exposure (needle stick, blood splash, sexual contact) to a person known to have hepatitis B, at least 30 days before clinical onset. If the source person's infection status cannot be proven, consider factor 9(2) as an alternative. For factor 9(2): obtain evidence of the person's location during service (postings, movement orders) and compile epidemiological data showing the area had at least 2% chronic hepatitis B prevalence at that time. This may require expert evidence from an epidemiologist or reliance on World Health Organization data. For factor 9(5): gather evidence that appropriate vaccination or post-exposure prophylaxis was not available or accessible before exposure. This could include medical records showing no vaccination was offered, or statements about the operational environment. For worsening factors: collect medication histories (immunosuppressants, radiotherapy records), blood test results (HIV, iron overload, diabetes), alcohol consumption records (self-report, medical notes), pregnancy records, and evidence of other hepatitis infections. For factor 9(18): document efforts to obtain clinical management and why management was not obtained (e.g., lack of follow-up, unavailability of antivirals). Step five: ensure that each factor relied upon is related to the person's relevant service. For onset factors, the factor itself must have occurred during or as a consequence of service. For worsening factors, section 10(2) requires that the infection was already present before or during service but did not arise out of service; the worsening factor must be related to service (e.g., immunosuppressive medication given for a service-related condition). Step six: compile a comprehensive submission mapping the evidence to the relevant factor, including a medical report that addresses clinical onset or worsening dates. For practitioners, a compliance checklist should be prepared for each file to avoid missing any factor. The instrument does not require a particular form of evidence; any probative material can be used, but medical records and expert reports carry the most weight. Finally, be aware that the instrument is binding on decision-makers; if the claim fails because no factor is raised, the only remedy is to seek review or to wait for further medical evidence that may support a future amendment to the SoP. The instrument does not provide a mechanism for seeking an exception or waiver. Compliance is therefore entirely about matching the claimant's factual matrix to the pre‑determined factors.